Due to its leading role in fighting infections, the human immune system has been the focus of many studies in the context of Coronavirus disease 2019 (COVID-19). In a worldwide effort, the scientific community has transitioned from reporting about the effects of the novel coronavirus on the human body in the early days of the pandemic to exploring the body’s many immunopathological and immunoprotecting properties that have improved disease treatment and enabled the development of vaccines. The aim of this review is to explain what happens to the immune system after recovery from COVID-19 and/or vaccination against SARS-CoV-2, the virus that causes the disease. We detail the way in which the immune system responds to a SARS-CoV-2 infection, including innate and adaptive measures. Then, we describe the role of vaccination, the main types of COVID-19 vaccines and how they protect us. Further, we explain the reason why immunity after COVID-19 infection plus a vaccination appears to induce a stronger response compared with virus exposure alone. Additionally, this review reports some correlates of protection from SARS-CoV-2 infection. In conclusion, we reinforce that vaccination is safe and important in achieving herd immunity.
Despite the effectiveness of antiretroviral therapy (ART) in suppressing HIV‐1 replication and reducing morbidity, viral eradication remains unachievable due to the persistence of latent reservoirs, particularly within memory CD4 + T cells. Dendritic cell (DC)‐based immunotherapeutic approaches have emerged as potential strategies to enhance antigen‐specific immune responses against HIV‐1. In this context, alpha‐type‐1 polarized DCs (αDC1) are notable for their capacity to produce interleukin‐12p70 (IL‐12p70) and induce robust Th1 and cytotoxic T lymphocyte (CTL) responses. However, clinical outcomes have been inconsistent, often influenced by host factors and methodological variability in DC generation and antigen delivery. The high genetic diversity of HIV poses challenges for vaccine development, whereas conserved regions such as gag and pol represent promising immunogenic targets. The present study aimed to evaluate a set of previously identified conserved HIV‐1 peptides for their ability to stimulate HIV‐specific T cell responses when presented by αDC1 in vitro in coculture assays using samples from a Brazilian cohort, as part of a preparatory phase for a clinical trial. For this purpose, monocytes were differentiated into αDC1 using IL‐4 and GM‐CSF. On Day 5, the cells were pulsed with 14–21mer HIV‐1 peptide pools (gag and pol) and matured by the addition of IFN‐α, IFN‐γ, IL‐1β, and TNF‐α. After 48 h, αDC1 were harvested and cocultured with autologous T cells for 6 or 20 days. Pulsed‐αDC1 were able to induce immune responses through the production of IFN‐γ in T cells, with the subpopulation of effector memory CD4 + T cells ( TEM ) being responsible for the production of this cytokine after reexposure to the HIV antigens.
Therapeutic vaccines based on monocyte‐derived dendritic cells have been shown to be promising strategies and may act as complementary treatments for viral infections, cancers, and, more recently, autoimmune diseases. Alpha‐type‐1‐polarized dendritic cells (aDC1s) have been shown to induce type‐1 immunity with a high capacity to produce interleukin‐12p70 (IL‐12p70). In the clinical use of cell‐based therapeutics, injectable solutions can affect the morphology, immunophenotypic profile, and viability of cells before delivery and their survival after injection. In this sense, preparing a cell suspension that maintains the quality of aDC1s is essential to ensure effective immunotherapy. In the present study, monocytes were differentiated into aDC1s in the presence of IL‐4 and GM‐CSF. On day 5, the cells were matured by the addition of a cytokine cocktail consisting of IFN‐α, IFN‐γ, IL‐1β, TNF‐α, and Poly I:C. After 48 hr, mature aDC1s were harvested and suspended in two different solutions: normal saline and Ringer’s lactate. The maintenance of cells in suspension was evaluated after 4, 6, and 8 hr of storage. Cell viability, immunophenotyping, and apoptosis analyses were performed by flow cytometry. Cellular morphology was observed by electron microscopy, and the production of IL‐12p70 by aDC1s was evaluated by ELISA. Compared with normal saline, Ringer’s lactate solution was more effective at maintaining DC viability for up to 8 hr of incubation at 4 or 22°C.